| Name | Title | Contact Details |
|---|
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento recently announced that NantPharma acquired the rights to Cynviloq™, which completed a successful TRIBECA study. Sorrento is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. In December 2014, Sorrento and NantWorks formed a global joint venture, now called Nantibody, to focus on immunotherapies for cancer. Also in December 2014, Sorrento and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast,® a Natural Killer (NK) cell-line based therapy, entered into an agreement to jointly develop CAR.TNK™ (Chimeric Antigen Receptor Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer and infectious diseases. In March 2015, Sorrento entered into a global collaboration with NantCell, a NantWorks company, to discover and develop immunotherapies against tumor neo-epitopes.
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with what we believe are innovative mechanisms of action. Our executive management team includes globally recognized specialists in central nervous system diseases addressing significant unmet medical needs. Our strategy is based on the following key principles: • Develop differentiated products based on biological and clinical insights related to the unmet needs of patients; • Conduct proof-of-principle trials in geographic areas with well characterized and validated patient populations where we have access to highly trained physicians with experience in conducting CNS-related trials; • Leverage the randomized, double-blind, placebo-controlled data from these trials to advance the clinical development of our products in multiple regulatory jurisdictions; • Selectively explore collaborations with leading pharmaceutical companies to maximize the value of our current product candidate portfolio, particularly in connection with the initiation of pivotal Phase III clinical trials and subsequent regulatory review, approval and commercialization; • Apply our management team`s expertise and current intellectual property portfolio to identify and explore additional indications relating to our current portfolio of compounds and to acquire additional product candidates
Indi Molecular provides PCCs for research and development in the fields for imaging agents for medical diagnostic imaging. Indi Imaging medical diagnostic research is provided to corporate partners, both as sponsored research or in partnership. Research and development using novel and custom PCCs, including PCCs that are membrane permeable, are provided for under the PCC Inside brand for uses that include antigen detection for both cell and tissue analysis, therapeutics or in vitro diagnostics.
Pulmatrix Inc is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases. GeneRide™ is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies With GeneRide™, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types.